Abivax Closes $920M Public Offering, Securing Funding into Q4 2029
ABVX has more than doubled off its 52-week low of $7.645.
Summary
Abivax has officially closed its public offering, raising $920 million in gross proceeds, or approximately $874.1 million net. This follows the initial offering announcement, its upsizing to $800 million, and the full exercise of the underwriters' option to purchase additional ADSs, which brought the total to $920 million on July 2nd. The company expects these net proceeds, combined with existing cash, to fund its operations into the fourth quarter of 2029. This significant capital infusion provides crucial financial runway for the commercialization of its lead drug candidate, obefazimod, especially after recent positive Phase 3 clinical trial results.
At the time of this announcement, ABVX was trading at $144.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3B. The 52-week trading range was $7.65 to $148.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.